Paracetamol in Patent Ductus Arteriosus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT02422966

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A (from the registry)
Registry
  • NCT NCT02422966
Other papers using this trial's data
  • Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial European journal of pediatrics, 2021-03 DOI, PubMed 32888085, PMC7886841 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02422966. Randomized; no masking; primary purpose treatment. Start 2015-12 (actual); primary completion 2019-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Paracetamol in Patent Ductus Arteriosus
Condition
Ductus Arteriosus, Patent
Intervention (Drug)
Paracetamol
Intervention (Drug)
Ibuprofen
Lead sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A (class: industry)

Record details

Record id
cardio:ct-nct02422966
Content hash
405b83ececcbfe5011b8469275fb1ef46cb360752deebfa30eb26c88aff95a64